#Sweden #Stockholm #Sobi #haemophilia #EAHAD

Sobi to Showcase Innovative Research at EAHAD 2026

Swedish Orphan Biovitrum AB, commonly known as Sobi, is set to make a significant impact at the 19th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD). Scheduled from February 3 to February 6, 2026, in Dublin, Ireland, this year’s event will spotlight crucial advancements in the treatment of haemophilia, particularly through Sobi's new data releases, including seven scientific abstracts.

One of the highlights will be an oral presentation about the Altuvoct treatment, showcasing findings from the three-year XTEND-ed study. This presentation will shed light on how Altuvoct can fundamentally enhance the lives of patients suffering from this rare blood disorder. Sobi is keen to spotlight its ongoing commitment to developing life-altering therapies tailored for individuals with severe haemophilia.

Dr. Lydia Abad-Franch, Sobi's Head of Research and Development and Chief Medical Officer, expressed her enthusiasm about the forthcoming conference, noting, "At EAHAD 2026, we will share long-term data from the XTEND-ed study of Altuvoct prophylaxis in haemophilia A. After three years of treatment, Altuvoct continues to offer protection to these patients, confirming the original registrational data. The few bleeds were managed well, and the data showed no unexpected safety issues. This underscores our belief in the potential of Altuvoct." These insights reflect Sobi's ongoing dedication to advancing treatment options for patients managing chronic diseases like haemophilia.

The full array of research findings Sobi plans to present at EAHAD 2026 includes:
1. Efanesoctocog alfa — Prophylaxis for severe haemophilia A, demonstrating third interim results from the XTEND-ed Long-Term Extension Study.
2. Insights from the FREEDOM study, particularly concerning physical activity and efficacy in patients with severe haemophilia A.
3. Clinical outcomes related to Efanesoctocog Alfa from various European results presented through the third interim analysis of XTEND-ed.
4. Examination of treatment approaches for managing bleeding episodes in patients, inclusive of adults and children with severe haemophilia A.
5. Evaluations of patient-physician alignment regarding joint damage in haemophilia A groups, leveraging real-world data from the CHESS III Study.
6. Psychosocial assessments and quality of life outcomes relative to joint damage in the same cohort, sourced from real-world contexts.
7. A presentation on real-world effectiveness and usage of rFIXFc in haemophilia B focusing on pediatric datasets from the B-MORE Study.

About Altuvoct

Altuvoct (efanesoctocog alfa) is a pioneering treatment option specifically indicated for bleeding management in those with haemophilia A. Its versatility allows application across various age groups and severity levels.

Collaborations in Development

The collaboration between Sobi and Sanofi is vital for the development and commercialization of Altuvoct. In regions designated as the Sobi territory, which largely includes Europe and parts of the Middle East, Sobi retains final rights for this development. Conversely, Sanofi oversees these processes in North America and other regions, ensuring a broad and effective deployment of this groundbreaking treatment.

About Sobi

As a global biopharma company, Sobi is focused on unlocking the possibilities of innovative treatments that can dramatically improve life for patients with rare diseases. With approximately 1,900 employees and a reported revenue of SEK 26 billion in 2024, Sobi is poised for continued growth while remaining steadfast in its commitment to patient care. Interested individuals can learn more about Sobi by visiting sobi.com or checking their LinkedIn profile.

With its promising advances and dedication to the haemophilia community, Sobi's presentations at EAHAD 2026 will not only highlight scientific progress but also reinforce the importance of ongoing research in improving patient outcomes in rare diseases.